Mesalazine

證據等級: L5

預測適應症: 7 個

Mesalazine: From Ulcerative Colitis to Congenital Hypotrichosis with Juvenile Macular Dystrophy

One-Sentence Summary

Mesalazine (5-ASA, mesalamine) is the active anti-inflammatory moiety of sulfasalazine, and is the cornerstone treatment for ulcerative colitis and other forms of inflammatory bowel disease. The TxGNN model’s highest-ranked prediction suggests Mesalazine may be effective for congenital hypotrichosis with juvenile macular dystrophy, yet no clinical trials or published literature currently support this direction, placing the evidence at L5 (model prediction only).

Quick Overview

Item	Content
Original Indication	Ulcerative colitis / Inflammatory bowel disease (IBD)
Predicted New Indication	Congenital Hypotrichosis with Juvenile Macular Dystrophy
TxGNN Prediction Score	99.65%
Evidence Level	L5
Philippines Market Status	✗ Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the current evidence pack. Based on well-established pharmacology, Mesalazine (5-aminosalicylic acid, 5-ASA) is produced when sulfasalazine is cleaved by colonic bacteria. It exerts anti-inflammatory effects primarily through inhibition of the NF-κB signalling pathway — thereby suppressing pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 — and by blocking cyclooxygenase (COX) and lipoxygenase (LOX) pathways to reduce prostaglandin and leukotriene production. Its efficacy in ulcerative colitis and Crohn’s disease is well-proven over decades of clinical use.

Congenital hypotrichosis with juvenile macular dystrophy (HJMD) is a rare autosomal recessive disorder caused by mutations in the CDH3 gene, which encodes P-cadherin. Affected individuals develop sparse hair from birth and progressive macular retinal degeneration leading to early-onset visual impairment. The underlying pathology is fundamentally structural and genetic — P-cadherin dysfunction disrupts cell–cell adhesion in hair follicle stem cells and the retinal pigment epithelium — with no established inflammatory component as a driver of disease.

There is currently no published biological rationale linking Mesalazine’s anti-inflammatory mechanism to CDH3 pathway dysfunction or macular degeneration. The high TxGNN prediction score most likely reflects a non-specific overlap of generalised inflammation nodes within the knowledge graph rather than any targeted biological relationship. This pattern is commonly observed for rare orphan diseases in graph-based prediction models, and this result should not be acted upon without first generating basic mechanistic evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a very high TxGNN score (99.65%), congenital hypotrichosis with juvenile macular dystrophy is a rare, genetically driven disease with no recognised inflammatory basis, and there is zero preclinical or clinical evidence that Mesalazine — or any anti-inflammatory agent — has any effect on CDH3 dysfunction or macular degeneration in this context.

To proceed, the following is needed:

Mechanistic feasibility study: Determine whether NF-κB inhibition or 5-ASA’s anti-inflammatory activity has any measurable effect on CDH3 expression, P-cadherin function, or retinal pigment epithelium integrity in cell or animal models
Knowledge graph audit: Clarify which shared nodes are driving the elevated TxGNN score (likely non-specific inflammation hubs); if the link is solely via generic inflammation nodes, biological specificity is insufficient to justify further development
Complete MOA and safety documentation: Full mechanism of action, key warnings, and contraindications for Mesalazine are currently unavailable and must be retrieved before any research initiation
Prioritise better-supported predictions: Two other TxGNN predictions for Mesalazine carry substantially stronger evidence — Osteoarthritis (L4, 3 publications including a 2024 Nature Communications mechanistic study) and Rheumatoid Arthritis (L3, 6 trials and 20 publications) — and warrant evaluation reports of their own before resources are allocated to this L5 prediction
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.